Results 301 to 310 of about 85,787 (336)
Some of the next articles are maybe not open access.
Drug resistance updates
AIMS Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease. Chemotherapy based on gemcitabine (GEM) remains the first-line drug for patients with advanced PDAC. However, GEM resistance impairs its therapeutic effectiveness.
Wenjie Huang +9 more
semanticscholar +1 more source
AIMS Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease. Chemotherapy based on gemcitabine (GEM) remains the first-line drug for patients with advanced PDAC. However, GEM resistance impairs its therapeutic effectiveness.
Wenjie Huang +9 more
semanticscholar +1 more source
2020
Large-scale sequencing analyses have transformed our understanding of PDAC and have defined several molecular taxonomies that now guide pre-clinical and clinical therapeutic development. The identification of molecularly defined subgroups of patients with distinct biological underpinnings and potential therapeutic vulnerabilities promises a step change
Holly Brunton +3 more
openaire +1 more source
Large-scale sequencing analyses have transformed our understanding of PDAC and have defined several molecular taxonomies that now guide pre-clinical and clinical therapeutic development. The identification of molecularly defined subgroups of patients with distinct biological underpinnings and potential therapeutic vulnerabilities promises a step change
Holly Brunton +3 more
openaire +1 more source
Epigenomic Changes Prime PDAC Metastasis
Cancer Discovery, 2017Abstract Widespread chromatin modifications and DNA methylation could be responsible for inducing the spread of pancreatic ductal adenocarcinoma cells to distant sites, according to recent research. The findings also implicate glucose metabolism as a driver of metastasis.
openaire +2 more sources
Biochemical Pharmacology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a poor 5-year survival rate of approximately 6%, mostly due to poor treatment response and early progression.
Ting Li +10 more
semanticscholar +1 more source
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a poor 5-year survival rate of approximately 6%, mostly due to poor treatment response and early progression.
Ting Li +10 more
semanticscholar +1 more source
KRAS degradation averts PDAC chemoresistance
Nature CancerEffectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
Laura Leonhardt, Matthias Hebrok
openaire +3 more sources
A Bacterial-Based Immunotherapy for PDAC
Cancer Discovery, 2022Abstract Researchers have used the bacterium Listeria monocytogenes to deliver tetanus toxoid to mice with pancreatic ductal adenocarcinoma. In these mice, previously vaccinated for tetanus, memory T cells were reactivated to subsequently destroy the tumors. Plans are underway to evaluate this approach in a phase I trial.
openaire +2 more sources
Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
Cancer Letters, 2020Neoantigens generated in neoplasms are a type of protein completely absent in healthy tissues. Therefore, anti-tumor immunity targeting neoantigens is highly specific, which provides an optional approach to boost tumor immunotherapy.
Hao Chen +5 more
semanticscholar +1 more source
Toward Ablative SBRT for Nonmetastatic PDAC
Cancer Discovery, 2023Abstract Combining a superoxide dismutase mimetic, avasopasem manganese, with stereotactic body radiation therapy may enable safe delivery of higher than standard radiation doses for patients with nonmetastatic, inoperable pancreatic adenocarcinoma.
openaire +2 more sources
DNA sequencing data of 41 paired PDAC patients and RNA-seq encing data of 41 normal PDAC ...
openaire +1 more source
openaire +1 more source
Glutamine metabolism drives PDAC
Science-Business eXchange, 2013Dana-Farber researchers have identified a glutamine metabolism pathway activated by oncogenic K-Ras in pancreatic cancers. The team found three different enzyme targets within the pathway that could be targeted to specifically inhibit tumor proliferation.
openaire +1 more source